Sandbox endocarditis: Difference between revisions
No edit summary |
No edit summary |
||
Line 62: | Line 62: | ||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table11" style="background: #FFFFFF;" | {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table11" style="background: #FFFFFF;" | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: | {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | ||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Native Valve Endocarditis Caused by Highly Penicillin-Susceptible Viridans Group Streptococci and Streptococcus bovis}} | ! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Native Valve Endocarditis Caused by Highly Penicillin-Susceptible Viridans Group Streptococci and Streptococcus bovis}} | ||
|- | |- | ||
Line 84: | Line 84: | ||
!style="padding: 0 5px; font-size: 80%; background: #F8F8FF" align=left | '''''PLUS''''' | !style="padding: 0 5px; font-size: 80%; background: #F8F8FF" align=left | '''''PLUS''''' | ||
|- | |- | ||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin| Gentamicin sulfate]] ฿ 3 mg/Kg per 24h 1 dose x 2 Wks''''' | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin| Gentamicin sulfate]] ฿ 3 mg/Kg per 24h 1 dose x 2 Wks''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatric dose}}'' | ! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatric dose}}'' | ||
Line 103: | Line 103: | ||
|- | |- | ||
|style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left |▸'''''[[Vancomycin|Vancomycin hydrochloride]] 40 mg/kg per 24 h IV in 2–3 equally divided doses''''' | |style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left |▸'''''[[Vancomycin|Vancomycin hydrochloride]] 40 mg/kg per 24 h IV in 2–3 equally divided doses''''' | ||
|- | |||
|Minimum inhibitory concentration ≤ 0.12 μg/mL. | |||
:† Preferred in most patients >65 y or patients with impairment of 8th cranial nerve function or renal function. | |||
:₳ Pediatric dose should not exceed that of a normal adult. | |||
:‡ 2-wk regimen not intended for patients with known cardiac or extracardiac abscess or for those with creatinine clearance of <20 mL/min, impaired 8th cranial nerve function, or Abiotrophia, Granulicatella, or Gemella spp infection; gentamicin dosage should be adjusted to achieve peak serum concentration of 3-4 μg/mL and trough serum concentration of >1 μg/mL when 3 divided doses are used; nomogram used for single daily dosing. | |||
:¶ Vancomycin therapy recommended only for patients unable to tolerate penicillin or ceftriaxone; vancomycin dosage should be adjusted to obtain peak (1 h after infusion completed) serum concentration of 30–45 μg/mL and a trough concentration range of 10–15 μg/mL | |||
:฿ Other potentially nephrotoxic drugs (eg, nonsteroidal antiinflammatory drugs) should be used with caution in patients receiving gentamicin therapy. Although it is preferred that gentamicin (3 mg/kg) be given as a single daily dose to adult patients with endocarditis due to viridans group streptococci, as a second option, gentamicin can be administered daily in 3 equally divided doses. | |||
|- | |- | ||
|} | |} |
Revision as of 17:15, 5 March 2014
Streptococci
▸ Click on the following categories to expand treatment regimens.
Native Valve Endocarditis Caused by Viridans Group Streptococci and Streptococcus bovis ▸ Viridans Group Streptococci and Streptococcus bovis Highly Penicillin-Susceptible ▸ Viridans Group Streptococci and Streptococcus bovis Relatively Penicillin Resistant (MIC >0.12 μg/mL- ≤ 0.5 μg/mL) Prosthetic Valves Endocarditis Caused by Viridans Group Streptococci and Streptococcus Bovis ▸ Viridans Group Streptococci and Streptococcus bovis Penicillin-susceptible strain (MIC ≤ 0.12 μg/mL) ▸ Viridans Group Streptococci and Streptococcus bovis Penicillin relatively or fully resistant strain (MIC >0.12 μg/mL) ▸ Viridans Group Streptococci and Streptococcus bovis Relatively Penicillin-Resistant Streptococci, MIC 0.2–0.5 µg/ml ▸ Relatively Penicillin-Resistant Streptococci, (MIC > 0.5 µg/ml) ▸ Unable to tolerate Penicillin or Ceftriaxone |
Native Valve Endocarditis Caused by Viridans Group Streptococci and Streptococcus bovisViridans Group Streptococci and Streptococcus bovis Highly Penicillin-Susceptible
Viridans Group Streptococci and Streptococcus bovis Relatively Penicillin Resistant (MIC >0.12 μg/mL- ≤ 0.5 μg/mL)
Prosthetic Valves Endocarditis Caused by Viridans Group Streptococci and Streptococcus BovisViridans Group Streptococci and Streptococcus bovis Penicillin-susceptible strain (MIC ≤ 0.12 μg/mL)
Viridans Group Streptococci and Streptococcus bovis Penicillin relatively or fully resistant strain (MIC >0.12 μg/mL)
Viridans Group Streptococci and Streptococcus bovis Relatively Penicillin-Resistant Streptococci, MIC 0.2–0.5 µg/ml
Relatively Penicillin-Resistant Streptococci, (MIC > 0.5 µg/ml)
Unable to tolerate Penicillin or Ceftriaxone
|